Description
CRYSVITA® (burosumab-twza) is a fibroblast growth factor 23 (FGF23) blocking antibody indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older.
Additional information
| Brand | CRYSVITA® 20mg |
|---|---|
| Generic name | Burosumab-twza for injection |
| Form | Parenteral |
| Strength | 20mg |
| Manufacturer | Kyowa Kirin |
| Documents | Either PO or prescription |
| Storage | 2-8°C temperature |
| Global delivery time | 10-20 days |
| Pay attention | Shipment should be organized from our Company with airlines only (Not FedEx, DHL, EMS, Aramex, UPS), at the specified storage condition along with one data logger. |
Reviews
There are no reviews yet.